Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Translations
    • Topics A-Z
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Translations
    • Topics A-Z
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Articles
  • Issues

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Genetics
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues

Share

December 2018; 4 (6) ArticleOpen Access

Delineating FOXG1 syndrome

From congenital microcephaly to hyperkinetic encephalopathy

Nancy Vegas, Mara Cavallin, Camille Maillard, Nathalie Boddaert, Joseph Toulouse, Elise Schaefer, Tally Lerman-Sagie, Dorit Lev, Barth Magalie, Sébastien Moutton, Eric Haan, Bertrand Isidor, Delphine Heron, Mathieu Milh, Stéphane Rondeau, Caroline Michot, Stephanie Valence, Sabrina Wagner, Marie Hully, Cyril Mignot, Alice Masurel, Alexandre Datta, Sylvie Odent, Mathilde Nizon, Leila Lazaro, Marie Vincent, Benjamin Cogné, Anne Marie Guerrot, Stéphanie Arpin, Jean Michel Pedespan, Isabelle Caubel, Benedicte Pontier, Baptiste Troude, Francois Rivier, Christophe Philippe, Thierry Bienvenu, Marie-Aude Spitz, Amandine Bery, Nadia Bahi-Buisson
First published November 7, 2018, DOI: https://doi.org/10.1212/NXG.0000000000000281
Nancy Vegas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mara Cavallin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Camille Maillard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathalie Boddaert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Toulouse
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elise Schaefer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tally Lerman-Sagie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dorit Lev
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barth Magalie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sébastien Moutton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Haan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bertrand Isidor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Delphine Heron
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathieu Milh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stéphane Rondeau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Michot
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephanie Valence
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sabrina Wagner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie Hully
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cyril Mignot
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alice Masurel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandre Datta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sylvie Odent
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathilde Nizon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leila Lazaro
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie Vincent
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin Cogné
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Marie Guerrot
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stéphanie Arpin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean Michel Pedespan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabelle Caubel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benedicte Pontier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Baptiste Troude
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francois Rivier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christophe Philippe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thierry Bienvenu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie-Aude Spitz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amandine Bery
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nadia Bahi-Buisson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Delineating FOXG1 syndrome
From congenital microcephaly to hyperkinetic encephalopathy
Nancy Vegas, Mara Cavallin, Camille Maillard, Nathalie Boddaert, Joseph Toulouse, Elise Schaefer, Tally Lerman-Sagie, Dorit Lev, Barth Magalie, Sébastien Moutton, Eric Haan, Bertrand Isidor, Delphine Heron, Mathieu Milh, Stéphane Rondeau, Caroline Michot, Stephanie Valence, Sabrina Wagner, Marie Hully, Cyril Mignot, Alice Masurel, Alexandre Datta, Sylvie Odent, Mathilde Nizon, Leila Lazaro, Marie Vincent, Benjamin Cogné, Anne Marie Guerrot, Stéphanie Arpin, Jean Michel Pedespan, Isabelle Caubel, Benedicte Pontier, Baptiste Troude, Francois Rivier, Christophe Philippe, Thierry Bienvenu, Marie-Aude Spitz, Amandine Bery, Nadia Bahi-Buisson
Neurol Genet Dec 2018, 4 (6) e281; DOI: 10.1212/NXG.0000000000000281

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
1675

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Objective To provide new insights into the FOXG1-related clinical and imaging phenotypes and refine the phenotype-genotype correlation in FOXG1 syndrome.

Methods We analyzed the clinical and imaging phenotypes of a cohort of 45 patients with a pathogenic or likely pathogenic FOXG1 variant and performed phenotype-genotype correlations.

Results A total of 37 FOXG1 different heterozygous mutations were identified, of which 18 are novel. We described a broad spectrum of neurodevelopmental phenotypes, characterized by severe postnatal microcephaly and developmental delay accompanied by a hyperkinetic movement disorder, stereotypes and sleep disorders, and epileptic seizures. Our data highlighted 3 patterns of gyration, including frontal pachygyria in younger patients (26.7%), moderate simplified gyration (24.4%) and mildly simplified or normal gyration (48.9%), corpus callosum hypogenesis mostly in its frontal part, combined with moderate-to-severe myelination delay that improved and normalized with age. Frameshift and nonsense mutations in the N-terminus of FOXG1, which are the most common mutation types, show the most severe clinical features and MRI anomalies. However, patients with recurrent frameshift mutations c.460dupG and c.256dupC had variable clinical and imaging presentations.

Conclusions These findings have implications for genetic counseling, providing evidence that N-terminal mutations and large deletions lead to more severe FOXG1 syndrome, although genotype-phenotype correlations are not necessarily straightforward in recurrent mutations. Together, these analyses support the view that FOXG1 syndrome is a specific disorder characterized by frontal pachygyria and delayed myelination in its most severe form and hypogenetic corpus callosum in its milder form.

Glossary

FBD=
forkhead binding domain

Mutations in the FOXG1 gene have been shown to cause a rare neurodevelopmental disorder. Initially described as a “congenital variant of Rett syndrome,”1,2 subsequent reports allowed delineation of the FOXG1 syndrome, which is now considered a distinct clinical entity.3,–,7

To date, more than 90 individuals with FOXG1 mutations have been described, mostly within small case series.5,7 The disorder comprises a complex constellation of clinical features, including severe postnatal microcephaly, deficient social reciprocity, combined stereotypies and dyskinesias, epilepsy, poor sleep patterns, and unexplained episodes of crying.3 In parallel to these clinical criteria, the importance of brain MRI features has been emphasized.1,3,8 However, the spectrum of MRI features in FOXG1 syndrome is yet to be fully defined.

FOXG1 encodes a transcription factor containing a highly conserved domain spanning from the forkhead binding domain (FBD) to the C-terminus and a variable N-terminus.9 FOXG1 mutations include frameshifts, deletions, and point mutations.7,10 A recent study suggests that more severe phenotypes are associated with truncating FOXG1 variants in the N-terminus and the FBD and milder phenotypes with missense variants in the FBD. The most significant differences were related to motor and speech development, while only borderline differences were found concerning corpus callosum anomalies, delayed myelination, and microcephaly.7

In light of these recent findings, the aim of this study was to provide a comprehensive overview of FOXG1-related clinical and imaging phenotypes by thorough analysis of a cohort of 45 clinically well-characterized patients with FOXG1 mutation and refine the phenotype-genotype correlation in FOXG1 syndrome.

Methods

We recruited patients with pathogenic or likely pathogenic FOXG1 mutations from different cohorts through a large national and international network. Genetic testing was performed by array comparative genomic hybridization (CGH) (5/45), Sanger sequencing (31/45), targeted panel high-throughput sequencing (4/45), and whole-exome sequencing (4/45).

Standard protocol approvals, registrations, and patient consents

The study was approved by the ethics committee of the University Hospital of Necker Enfants Malades, Paris, France and the relevant local institutional review boards. Parental written informed consent was obtained for all affected patients.

All patients were personally known to at least 1 of the co-authors and were reexamined for the purpose of the study. Five patients had been reported previously and were reassessed for the study.8,11,12 Standardized clinical information was recorded. Movement disorders were characterized in person by investigators and classified according to established criteria.13 Epileptic seizures were classified according to the recommendations of the Commission on Classification and Terminology of the International League Against Epilepsy.

In addition, for patients filmed, we obtained additional authorization for disclosure of any recognizable persons in videos.

The genetic testings were performed in accordance with the respective national ethics guidelines and approved by the local authorities in the participating study centers.

MRI studies

As the MRI studies were performed over a period of 10 years at many different imaging centers and on many different types of MR scanners, the imaging techniques that were used differed substantially, although a majority had at least axial and sagittal T1-weighted and axial T2-weighted and fluid-attenuated inversion recovery (FLAIR) sequences. Imaging assessment was based on agreement between 2 investigators (N.B. and N.B.-B.) who reviewed the images. Each made initial evaluations independently, and any disagreements regarding the final conclusion were resolved by consensus.

Statistical analysis

All statistical analyses were performed in GraphPad Prism version 6.00. Data are described as mean ± SEM. Differences were evaluated using the 2-way analysis of variance with multiple comparison tests.

The study was approved by the ethics committee of the University Hospital of Necker Enfants Malades, Paris, France and the relevant local institutional review boards. Parental written informed consent was obtained for all affected patients.

Results

Our cohort totaled 45 patients with FOXG1 mutations, 22 males and 23 females ranging in age from 19 months to 42 years (median: 5.73 years) at the time of evaluation (table e-1 links.lww.com/NXG/A97).

A total of 37 FOXG1 different heterozygous mutations were identified, of which 18 are novel. They comprised 32 small intragenic mutations and 5 large deletions of the whole FOXG1 locus. All mutations were de novo, except 1 reported previously as a germinal mosaic.12 Point mutations were mostly frameshifts (14/32; 43.75%) and missense mutations (12/32; 37.5%), with a small number of nonsense (4/32; 12.5%) and in-frame mutations (2/32; 6.25%) (figure 1, A and B). Three recurrent mutations, c.460dupG, c.256dupC, and c.256delC, were identified.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1 Schematic representation of FOXG1 gene, protein domain structure, and positions of FOXG1 mutations

(A) Schematic representation of FOXG1 gene and (B) FOXG1 protein domain structure and positions of the variations identified: N-terminal domain; FBD domain (forkhead DNA binding domain, amino acids 181–275), GBD domain (Groucho binding domain, amino acids 307–317), JBD domain (JARID1B binding domain, amino acids 383–406), and C-terminal domain are indicated. Mutations are located all along the FOXG1 gene, within different protein domains. Missense mutations are predominantly located in the FBD (91.7%), whereas frameshift mutations are more prominent in the N-terminal domain (57.1%). The novel variants described in this article are highlighted in bold and the recurrent variants are underlined with the corresponding number of recurrences indicated in brackets. FBD = forkhead binding domain; GBD = Groucho binding domain; JBD = JARID1B binding domain.

Clinical presentation in patients with FOXG1 mutations

Patients first came to medical attention at a median age of 3 months (birth to 20 months) because of developmental delay and microcephaly (15/45; 33.3%) or with lack of eye contact, or strabismus (16/45; 35.6%). Epileptic seizures or movement disorder were less common (4/45; <10%). In 5 cases (11.1%), brain anomalies were diagnosed prenatally.

At birth, a majority of patients had normal body measurements and low normal birth head size (38/43; 88.4%). Severe postnatal microcephaly (−4 to −6 SD) became apparent after the age of 1 month.

At the age of the last evaluation (median: 5 years; 19 months to 42 years), all patients had profound developmental delay, with permanent esotropia (38/42; 90.7%) (video 1 links.lww.com/NXG/A99). Hand use was severely limited to involuntary gross manipulation (13/44; 29.5%) (video 2 links.lww.com/NXG/A100). On examination, a complex movement disorder was the most prominent feature characterized by generalized hyperkinetic and dyskinetic movements that was present at rest and worsened with attempts to movement (videos 3 and video 4 links.lww.com/NXG/A101 and links.lww.com/NXG/A102), with orolingual dyskinesias (12/33; 36.4%) (video 5 links.lww.com/NXG/A103); 34 of 43 patients (79.1%) also showed hand stereotypies, consisting of hand pressing/wringing or hand mouthing (videos 6 and video 7 links.lww.com/NXG/A104, links.lww.com/NXG/A105), which are unusual in the context of dyskinetic movement disorders. Thirty-two of 44 patients (72.7%) had feeding difficulties associated with gastroesophageal reflux (videos 8 and video 9 links.lww.com/NXG/A106 and links.lww.com/NXG/A107). Sleep problems were frequent (27/42; 64.3%) and included multiple nocturnal awakenings or difficulties in falling asleep with irritability and inconsolable crying or inappropriate laughing (25/40; 62.5%). Seizures were documented in 77.8% (35/45) of patients and occurred at a mean age of 2.5 years (range: 2 days to 12 years). Generalized tonic or tonic-clonic seizures were the most frequent seizure type (21/35; 60%). Of the 35 patients, 17 (48.6%) developed refractory epilepsy with multiple seizure types and 5 (14.3%) experienced at least 1 episode of status epilepticus (table 1).

Video 1

Patient Lyo01 showing permanent esotropia, but preserved eye contact. Note the limb and orofacial dyskinesiaDownload Supplementary Video 1 via http://dx.doi.org/10.1212/000281_Video_1

Video 2

Patient Lyo01 touching musical object with his right hand and at the same time showing hand to mouth stereotypy. Note the hyperkinesia in his movement patternDownload Supplementary Video 2 via http://dx.doi.org/10.1212/000281_Video_2

Video 3

Patient Ang01 showing generalized dyskinesia and hyperkinesia. Note the dystonic posture of the upper limbDownload Supplementary Video 3 via http://dx.doi.org/10.1212/000281_Video_3

Video 4

Patient Aix01 showing generalized hyperkinetic movement disorder with choreic and myoclonic componentsDownload Supplementary Video 4 via http://dx.doi.org/10.1212/000281_Video_4

Video 5

Patient Aix01 showing excessive drooling mild orobuccal dyskinesia with generalized dyskinesia combined with choreic and myoclonic componentsDownload Supplementary Video 5 via http://dx.doi.org/10.1212/000281_Video_5

Video 6

Patient Ang01 showing intermittent hand to mouth stereotypiesDownload Supplementary Video 6 via http://dx.doi.org/10.1212/000281_Video_6

Video 7

Patient Im07 showing intermittent hand stereotypies at the midlineDownload Supplementary Video 7 via http://dx.doi.org/10.1212/000281_Video_7

Video 8

Patient Ang01 showing feeding difficulties related to orobuccal dyskinesia. Note the dystonic posture of the upper limbDownload Supplementary Video 8 via http://dx.doi.org/10.1212/000281_Video_8

Video 9

Patient Im07 showing feeding difficulties related to orobuccal dyskinesia. Note the exotropia and the permanent movement of the upper limbDownload Supplementary Video 9 via http://dx.doi.org/10.1212/000281_Video_9

View this table:
  • View inline
  • View popup
Table 1

Individual data on epilepsy and MRI pattern on 45 patients with de novo FOXG1 mutations/deletions

Because, FOXG1 mutations had been previously associated with congenital Rett variant, we examined the prevalence of congenital Rett-supportive manifestations. Overall, 2 of 21 females (9.5%) and 1 of 21 males (4.76%) fulfilled the diagnostic criteria for Rett syndrome14 (table e-2 links.lww.com/NXG/A98).

Brain images

Patients with FOXG1 syndrome showed a variable degree of gyration, moderate-to-severe myelination delay or white matter loss (64.4%), and abnormal corpus callosum (95.6%). From our detailed review of these imaging studies, we were able to delineate 3 groups of severity of gyration defect that are most easily appreciated with multiple views in several planes, as shown in figures 2, A-L and 3, A-H.

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2 Representative MRI of pachygyric frontal cortex in FOXG1 patients

Representative images at the level of centrum semiovale in axial T1-weighted (A, E, I) and T2-weighted (B, F, J) MRI, at the level of lateral ventricles (third column) and midline sagittal (right column). Each row shows images from the same patient respectively: (A–D) Str02 aged 19 months; (E–H) Ang01 aged 23 months; (I–L) Rou01, aged 34 months. The cortex appears mildly thick with a clear predominance in the frontal lobes. The appearance of pachygyria is accentuated by the underdevelopment of frontal lobes. T2-weighted (C, G, K) MRI at the level of the internal capsule showing associated myelination delay, with mature myelin only visible in both internal capsules (G and K). T1-weighted midline sagittal sections showing the wide range of appearance of the corpus callosum, from hypoplastic and thin (D, L) to thick with underdevelopment of the genu (H).

Figure 3
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3 Changing appearance of the frontal cortex with age associated with increasing myelination

Representative images from 2 patients: Im11 p.Gln86Profs*35 (A–D) and Im09 p.Glu154Glyfs*301 (E–H). (A and B) Images obtained when the patient was 6 months old. T2-weighted image (A) shows normal thickness of both frontal lobes but delayed myelination. T1-weighted image (B) shows a pachygyric cortex in the same region. (C and D) Images obtained when the patient was 2 years 6 months. T2-weighted image (C) of the frontal lobe shows mildly thickened cortex, probably because of the poor myelination of the subcortical white matter. (E and F) Images obtained when the patient was 1 year 8 months. In the frontal lobe, T2-weighted (E) and T1-weighted (F) images show the same pattern of pachygyric cortex and severely delayed myelination (E). (G and H) At 3 years, the T2-weighted image (G) shows significant improvement of myelination, although still delayed in the frontal subcortical region: the T1-weighted image (H) shows mildly simplified gyral pattern, with no pachygyria.

The first gyral pattern, the most severe, consisted of pachygyria, with thickened cortex with frontal lobe predominance (12/45; 26.7%). This pattern was seen in the youngest patients (mean age 1.8 years) and was accentuated by the underdevelopment of the frontal lobes and the reduced volume of the subcortical white matter. In this group, myelination delay was prominent, ranging from severe (7/11; 63.6%) to moderately delayed (4/11; 36.4%). The most common corpus callosum anomaly was anterior hypogenesis, mostly affecting the genu and the rostrum (6/11; 54.5%) (figure 2, A-L). Sequential MRI performed during the first years of life showed that this pachygyric appearance can be overestimated between the ages of 12 and 24 months because of the immature myelination (figure 3, A-H). Delayed myelination improved with age, and no case of hypomyelination or dysmyelination was observed after the age of 5 years.

The second gyral pattern of intermediate severity met the subjective criteria of moderately simplified gyral pattern.15 This pattern was observed in 24.4% (11/45) of patients with mean age of 3.1 years. In this group, myelination was moderately to severely delayed. The corpus callosum showed a wide range of anomalies, including complete agenesis (5/11; 45.5%), global hypoplasia (3/11; 27.3%), and anterior hypogenesis (3/11; 27.3%).

The third gyral pattern, the least severe, consisted of mildly simplified to normal gyral pattern. These patients (22/45; 48.9%) were older than the 2 previous groups (mean age 6.1 years). White matter anomalies were mostly mild or absent (14/22; 63.6%), and the corpus callosum was hypogenetic in its anterior part in the majority of cases (14/22; 63.6%) (figure e-1 links.lww.com/NXG/A91).

Genotype-phenotype relationships

To assess genotype-phenotype associations in FOXG1 syndrome, we investigated the correlation between the score of selected FOXG1 criteria in the whole cohort and 5 genetic subgroups (e-results) (table 2).

View this table:
  • View inline
  • View popup
Table 2

Clinical and neuroimaging features related to the FOXG1 genotype groups

Patients with N-terminal mutations and FOXG1 deletions showed the highest global severity scores, while those with FBD frameshift and nonsense mutations showed the lowest global severity scores (p < 0.05). Patients with FBD missense and C-terminal domain mutations tended to have lower global severity scores, although the differences were not significant because of the small size of these groups (figure e-2A links.lww.com/NXG/A92).

When covariance analysis was performed in the whole cohort, we found significant positive covariance of gyral and myelination pattern scores, suggesting that whatever the type of FOXG1 mutation, the most severe cortical anomaly (i.e., pachygyria) is correlated with the most severe myelination delay, further reinforcing the fact that this cortical anomaly may be overestimated because of the abnormal myelination of the subcortical fibers. Further analyses showed significant and distinct covariance relationships in which the MRI pattern appeared the most relevant criteria in distinguishing the genetic groups (figures e-3 links.lww.com/NXG/A93 and e-4 links.lww.com/NXG/A94).

Interesting data also came from the analysis of patients with recurrent frameshift mutations c.460dupG and c.256dupC. Remarkably, among the patients with c.460dupG, we found significant differences in clinical and imaging presentations, demonstrating that genotype-phenotype correlation is not straightforward in FOXG1 syndrome. On MRI, this mutation resulted in a spectrum of corpus callosum anomalies, from complete agenesis to global hypoplasia (figure e-5 links.lww.com/NXG/A96). By contrast, the 3 patients with the c.256dupC had a more consistent phenotype.

Discussion

Foxg1 is a transcription factor that plays nonredundant roles in brain development, such that loss of a single copy of the gene severely affects brain formation, and knock-out mice cannot survive after birth.9,16 Consequently, it is not surprising that all mutations identified in humans are heterozygous and result in noticeable changes in brain size and mental development early in childhood. To date, FOXG1 has been linked to a wide range of human congenital brain disorders.1,–,7,17,–,19 In this study, we describe detailed clinical and neuroradiological data on 45 patients with pathogenic single nucleotide variants and copy number variations affecting FOXG1. This is one of the largest cohort of patients with FOXG1 syndrome and focuses on FOXG1 point mutations, which affect both sexes equally. The aim of this study was to refine the phenotypic spectrum of FOXG1 syndrome and its natural history and to further investigate genotype-phenotype correlations. In keeping with previously published FOXG1-associated clinical features, we found FOXG1 syndrome to be associated with severe postnatal microcephaly (−4 to −6 SD), dyskinetic-hyperkinetic movement disorders, visual impairment, epilepsy, stereotypies, abnormal sleep patterns, and unexplained episodes of crying.1,3,5,–,8,18,20,–,23

Our data clearly confirm that head circumference is usually normal to borderline small at birth and evolves during infancy to severe microcephaly below −3 SD, with normal somatic growth. Although no longitudinal data on head circumference are available from our series, it is interesting to note that microcephaly was the first concern in one-third of the cohort at the mean age of 3.47 months, suggesting that the slowdown in head growth occurs earlier than previously described. Of note, FOXG1-related postnatal microcephaly is characterized by underdevelopment of the frontal lobes, a unique pattern that does not occur in other causes of progressive microcephaly.24 This underdevelopment of frontal lobes can be associated with a mildly to moderately simplified gyral pattern and reduced white matter or in the youngest patients with a pachygyric appearance. We observed this pattern on T2-weighted images in infants who showed mild gyral simplification later in childhood. The clue to the cause of the 2 patterns came from studying serial MRI of patients Im09 and Im11. Frontal pachygyria, which was observed at 6 months of age, changed into mild gyral simplification at 2.5 years of age. This finding suggested that the 2 cortical patterns did not represent differences of morphology but instead, differences in the maturity of the subcortical white matter. It is noteworthy that this changing appearance has been observed previously in polymicrogyria.25,26

Another imaging hallmark of FOXG1 disorder is the delayed myelination. While delayed myelination has a similar appearance to hypomyelination on a single MRI, especially if done at an early age, sequential studies can distinguish between them by demonstrating increasing myelin content in delayed myelination.27 This evolution of delayed myelination toward normalization in childhood is not specific to FOXG1 syndrome, as it has been observed in other developmental disorders, such as MCT8 deficiency and Xq28 duplication involving MECP2 or SPTAN1 encephalopathy.27,–,29

Taken together with the published literature, we suggest that FOXG1 syndrome is a disorder in which hypogenetic corpus callosum is the most frequent finding. More specifically, corpus callosum malformations in FOXG1 syndrome are frontal predominant, similar to the gyral abnormality, suggesting that the same pathogenic mechanism operates for both the frontal cortical abnormalities and the callosal abnormalities. Complete agenesis occurs occasionally and is likely to represent the most severe end of the spectrum of pathogenic mechanisms underlying hypoplasia. This also illustrates that hypoplasia and agenesis are related to a similar mechanism and that genetic modifiers influence the severity of the callosal phenotype.30 Of interest, the severity of corpus callosum anomaly does not correlate with the degree of microcephaly, the degree of myelination abnormality, or the degree of gyral abnormalities. This contrasts with data from congenital microcephaly that showed a correlation between the degree of microcephaly and the severity of the associated callosal anomaly.31

Hyperkinetic movement disorders have been recognized to be a key feature in FOXG1 syndrome since its original description.6,18 Our data show that movement disorder is rarely the presenting feature of FOXG1 syndrome; this has not been stressed previously. It is important that the combination of hand stereotypes, mostly hand to mouth, with generalized dyskinesia is one of the key characteristics of FOXG1 syndrome that distinguishes it from other monogenic hyperkinetic movement disorders or neurodegenerative diseases.6,32 The hyperkinetic movement disorder, although affecting quality of life, was stable over time, never evolved into status dystonicus, and did not lead to any of the complications of severe dystonia that can observed in other developmental or degenerative neurologic disorders.6,32

A previous report suggested that FOXG1 syndrome could be classified as an epileptic-dyskinetic encephalopathy18 like ARX- and STXBP1-related encephalopathies. Our data show that epilepsy is not a consistent feature, unlike dyskinetic-hyperkinetic movements. Although epilepsy affected 79% of patients reported here, which is within the range of previous reports (from 57%7 to 86%5), it did not show a particular seizure pattern that could help the clinician to define a specific epilepsy syndrome.

Since the first report that FOXG1 mutations can be responsible for congenital Rett variant, a number of publications have emphasized the differences between these disorders.33 Here, by applying the congenital Rett variant criteria,14 we confirm that the majority of patients with the FOXG1 syndrome do not meet the criteria for congenital Rett variant. At all ages, FOXG1 syndrome is more severe with respect to ambulation, reciprocity, and receptive language and has more disordered sleep, compared with Rett syndrome, as well as lacking the regression observed in Rett syndrome. These findings further reinforce that FOXG1 disorder is clinically separable from Rett syndrome, with distinct clinical presentation and natural history. It is important that patients with FOXG1 disorder receive appropriate counseling about medical comorbidities and natural history related to their disorder, avoiding the confusion with Rett syndrome.

The number of reported FOXG1 mutations is now large enough to search for genotype-phenotype correlations in FOXG1 syndrome. We observed that patients carrying mutations in the N-terminal domain and large deletion of FOXG1, which are the most common mutation types, show the most severe presentation and MRI anomalies, while those carrying mutations in the FBD or C-terminal domain were less severely affected. In previous series, a milder phenotype was observed in patients with missense variants in the FBD conserved site.7 However, the differences were found in items related to sitting, walking, and functional hand use, which are commonly severely impaired in all FOXG1 mutation patients.7 Using covariance and cluster analyses, we highlighted relationships between gyral and myelination patterns in patients with FOXG1 disorder. However, identical hotspot mutations c.256dupC and c.406dupG can be associated with highly variable features, such as variable epilepsy severity or degree of corpus callosum anomalies, underlining the importance of being cautious about predicting phenotype on the basis of genotype in the context of genetic counseling. This suggests that factors beyond the primary mutation can influence disease severity, including genetic modifiers and epigenetic and environmental factors.

The complexity and the poor reproducibility of genotype-phenotype relationships in FOXG1 syndrome probably reflects the pleiotropic and nonredundant roles of Foxg1 in vertebrate brain development.

This study, one of the largest to date, provides evidence that FOXG1 mutations are responsible for a specific and recognizable neurodevelopmental disorder with a high degree of variability. We have expanded the phenotypic spectrum by defining 3 key brain imaging features of FOXG1 syndrome, noting that the degree of cortical abnormality is not correlated with the severity of the corpus callosum malformation. Moreover, our data confirm that mutations leading to the loss of the FBD domain, lead to the most severe clinical presentation of FOXG1 syndrome. The pathophysiology of such complex genotype-phenotype relationships reflects the pleiotropic and nonredundant roles of Foxg1 during development.

Affiliation

From the Imagine Institute (N.V., M.C., C. Maillard, A.B., N.B.-B.), INSERM UMR 1163, Paris Descartes University, Necker Enfants Malades Hospital, Paris, France; Pediatric Neurology APHP—Necker Enfants Malades Hospital (M.C., M.H., N.B.-B.), Paris, France; Pediatric Radiology (N.B.), APHP—Necker Enfants Malades Hospital, Paris, France; Image—Imagine Institute (N.B.), INSERM UMR 1163, Paris Descartes University, Necker Enfants Malades Hospital, Paris, France; Department of Paediatric Clinical Epileptology (J.T.), Sleep Disorders and Functional Neurology, University Hospitals of Lyon (HCL), France; Service de Génétique médicale (E.S.), Hôpitaux Universitaires de Strasbourg, IGMA, France; Pediatric Neurology (T.L.-S.), Wolfson Medical Center, Tel Aviv, Israël; Wolfson Molecular Genetics Laboratory (D.L.), Wolfson Medical Center, Tel Aviv, Israël; Neurometabolism Department (B.M.), Angers Hospital and University, France; Centre de Génétique et Centre de Référence Maladies Rares Anomalies du Développement (S.M., A.M.), CHU Dijon, France; South Australian Clinical Genetics Service (E.H.), SA Pathology (at Royal Adelaide Hospital), and School of Medicine, University of Adelaide, Australia; Service de Génétique Médicale (B.I., M.N., M.V., B.C.), CHU Nantes, France; Département de Génétique et Centre de Référence Déficiences Intellectuelles de Causes Rares (D.H., C. Mignot), Hôpital de la Pitié-Salpêtrière, APHP, Paris, France; GMGF (M.M.), INSERM UMR_S910, Aix-Marseille University, Pediatric Neurology Unit, Timone Children Hospital, Marseille, France; Department of Neonatal Medicine (S.R.), Rouen University Hospital, Haute-Normandie, France; Department of Medical Genetics (C. Michot), Reference Center for Skeletal Dysplasia, INSERM UMR 1163, Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia, Paris Descartes-Sorbonne Paris Cité University, AP-HP, Institut Imagine, and Hôpital Universitaire Necker-Enfants Malades, Paris, France; APHP (S.V.), GHUEP, Hôpital Trousseau, Neurologie Pédiatrique, Paris, France; GRC ConCer-LD (S.V.), Sorbonne Universités, UPMC Univ 06, Paris, France; Hôpital Nord Franche Comte (S.W.), CH HNFC—Site de Belfort, France; Pediatrics (A.D.), University of Basel Childrens' Hospital, Switzerland; CHU Rennes (S.O.), Service de Génétique Clinique, CNRS UMR6290, Université Rennes1, France; Service de Pédiatrie (L.L.), Centre Hospitalier de la Côte Basque, Bayonne, France; Department of Genetics (G.A.M.), Rouen University Hospital, France; Service de Génétique (A.S.), Hôpital Bretonneau, Tours, France; Service de Neurologie Pédiatrique (J.M.P.), Hôpital Pellegrin-Enfants, CHU de Bordeaux, France; Pédiatrie générale (I.C.), Hôpital de Lorient, France; Génétique Médicale—CHU Estaing CLERMONT-FERRAND (B.P., B.T.), France; Service de Neurologie Pédiatrique (F.R.), Hôpital Gui de Chauliac, CHRU de Montpellier, France; Equipe Génétique des Anomalies du Développement (C.P.), INSERM UMR1231, Université de Bourgogne-Franche Comté, Dijon, France; Laboratoire de Génétique chromosomique moléculaire (C.P.), Plateau technique de Biologie, CHU, Dijon, France; Laboratory of Biochemistry and Molecular Genetics (T.B.), HUPC Paris Centre, Cochin Hospital, Paris, France; National Rare Disease Center—Centre de Référence “déficiences intellectuelles de causes rares” (M.-A.S.), Strasbourg University Hospital, France; and National Rare Disease Center—Centre de Référence “déficiences intellectuelles de causes rares” (N.B.-B.), AP-HP, Necker Enfants Malades, Paris, France.

Author contributions

N. Vegas, M. Cavallin, C. Maillard: study concept and design, analysis and acquisition of clinical and molecular data. N. Boddaert: analysis and acquisition of MRI data. J. Toulouse, E. Schaefer, T. Lerman-Sagie, D. Lev, B. Magalie, S. Moutton, E. Haan, B. Isidor, D. Heron, M. Milh, S. Rondeau, C. Michot, S. Valence, S. Wagner, M. Hully, C. Mignot, A. Masurel, A. Datta, S. Odent, M. Nizon, L. Lazaro, M. Vincent, B. Cogné, G.A. Marie, A. Stéphanie, J.M. Pedespan, I. Caubel, B. Pontier, B. Troude, F. Rivier, M.-A. Spitz: acquisition of data and follow-up of the patients. C. Philippe and T. Bienvenu: analysis molecular data. A. Bery and N. Bahi-Buisson: study supervision, concept and critical revision of manuscript for intellectual content.

Study funding

Research reported in this publication was supported by the Agence Nationale de la Recherche (ANR-16-CE16-0011 MC, AB, NBB), the Fondation Maladies Rares, and DESIRE (grant agreement 602531). The project was also supported by the European Network on Brain Malformations (COST Action CA16118). The authors have no conflict of interest to declare.

Disclosure

N. Vegas, M. Cavallin, C. Maillard, N. Boddaert, J. Toulouse, E. Schaefer report no disclosures. T. Lerman-Sagie has served on the editorial boards of the Journal of Child Neurology, Harefuah, and the European Journal of Paediatric Neurology. D. Lev has received research support from the Sackler School of Medicine (Tel Aviv University). M. Barth and S. Moutton report no disclosures. E. Haan has received research support from the Lipedema Foundation (USA). B. Isidor and D. Heron report no disclosures. M. Milh has received speaker honoraria from Shire and Cyberonics. S. Rondeau, C. Michot, S. Valence, S. Wagner, M. Hully, C. Mignot, A. Masurel, A. Datta, S. Odent, M. Nizon, L. Lazaro, M. Vincent, B. Cogné, A.M. Guerrot, S. Arpin, J.M. Pedespan, I. Caubel, B. Pontier, B. Troude, F. Rivier, C. Philippe, T. Bienvenu, M. Spitz, and A. Bery report no disclosures. N. Bahi-Buisson has received research support from Agence Nationale de la recherche, Fondation pour la Recherche Médicale, Fondation NRJ—Institut de France, and the EU-FP7 project GENECODYS. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NG.

Acknowledgment

The authors would like to thank the affected individuals and their families for participation in this study, as well as the clinicians in charge of these patients who may not be cited. The authors would like to sincerely thank Prof Alessandra Pierani for her critical reading of the manuscript and helpful comments on our findings.

Footnotes

  • Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NG.

  • The Article Processing Charge was funded by the authors.

  • Received March 24, 2018.
  • Accepted in final form July 12, 2018.
  • Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Ariani F,
    2. Hayek G,
    3. Rondinella D, et al
    . FOXG1 is responsible for the congenital variant of Rett syndrome. Am J Hum Genet 2008;83:89–93.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Mencarelli MA,
    2. Spanhol-Rosseto A,
    3. Artuso R, et al
    . Novel FOXG1 mutations associated with the congenital variant of Rett syndrome. J Med Genet 2010;47:49–53.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Kortum F,
    2. Das S,
    3. Flindt M, et al
    . The core FOXG1 syndrome phenotype consists of postnatal microcephaly, severe mental retardation, absent language, dyskinesia, and corpus callosum hypogenesis. J Med Genet 2011;48:396–406.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Ellaway CJ,
    2. Ho G,
    3. Bettella E, et al
    . 14q12 Microdeletions excluding FOXG1 give rise to a congenital variant Rett syndrome-like phenotype. Eur J Hum Genet 2013;21:522–527.
    OpenUrlPubMed
  5. 5.↵
    1. Seltzer LE,
    2. Ma M,
    3. Ahmed S, et al
    . Epilepsy and outcome in FOXG1-related disorders. Epilepsia 2014;55:1292–1300.
    OpenUrlPubMed
  6. 6.↵
    1. Papandreou A,
    2. Schneider RB,
    3. Augustine EF, et al
    . Delineation of the movement disorders associated with FOXG1 mutations. Neurology 2016;86:1794–1800.
    OpenUrl
  7. 7.↵
    1. Mitter D,
    2. Pringsheim M,
    3. Kaulisch M, et al
    . FOXG1 syndrome: genotype-phenotype association in 83 patients with FOXG1 variants. Genet Med 2018;20:98–108.
    OpenUrl
  8. 8.↵
    1. Bahi-Buisson N,
    2. Nectoux J,
    3. Girard B, et al
    . Revisiting the phenotype associated with FOXG1 mutations: two novel cases of congenital Rett variant. Neurogenetics 2010;11:241–249.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Kumamoto T,
    2. Hanashima C
    . Evolutionary conservation and conversion of Foxg1 function in brain development. Dev Growth Differ 2017;59:258–269.
    OpenUrl
  10. 10.↵
    1. Krishnaraj R,
    2. Ho G,
    3. Christodoulou J
    . RettBASE: Rett syndrome database update. Hum Mutat 2017;38:922–931.
    OpenUrl
  11. 11.↵
    1. Le Guen T,
    2. Bahi-Buisson N,
    3. Nectoux J, et al
    . A FOXG1 mutation in a boy with congenital variant of Rett syndrome. Neurogenetics 2011;12:1–8.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Diebold B,
    2. Delepine C,
    3. Nectoux J,
    4. Bahi-Buisson N,
    5. Parent P,
    6. Bienvenu T
    . Somatic mosaicism for a FOXG1 mutation: diagnostic implication. Clin Genet 2014;85:589–591.
    OpenUrl
  13. 13.↵
    1. Sanger TD,
    2. Chen D,
    3. Fehlings DL, et al
    . Definition and classification of hyperkinetic movements in childhood. Mov Disord 2010;25:1538–1549.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Neul JL,
    2. Kaufmann WE,
    3. Glaze DG, et al
    . Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol 2010;68:944–950.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Adachi Y,
    2. Poduri A,
    3. Kawaguch A, et al
    . Congenital microcephaly with a simplified gyral pattern: associated findings and their significance. AJNR Am J Neuroradiol 2011;32:1123–1129.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Xuan S,
    2. Baptista CA,
    3. Balas G,
    4. Tao W,
    5. Soares VC,
    6. Lai E
    . Winged helix transcription factor BF-1 is essential for the development of the cerebral hemispheres. Neuron 1995;14:1141–1152.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Striano P,
    2. Paravidino R,
    3. Sicca F, et al
    . West syndrome associated with 14q12 duplications harboring FOXG1. Neurology 2011;76:1600–1602.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Cellini E,
    2. Vignoli A,
    3. Pisano T, et al
    . The hyperkinetic movement disorder of FOXG1-related epileptic-dyskinetic encephalopathy. Dev Med Child Neurol 2016;58:93–97.
    OpenUrl
  19. 19.↵
    1. Mariani J,
    2. Coppola G,
    3. Zhang P, et al
    . FOXG1-dependent dysregulation of GABA/glutamate neuron differentiation in autism spectrum disorders. Cell 2015;162:375–390.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. De Bruyn C,
    2. Vanderhasselt T,
    3. Tanyalcin I, et al
    . Thin genu of the corpus callosum points to mutation in FOXG1 in a child with acquired microcephaly, trigonocephaly, and intellectual developmental disorder: a case report and review of literature. Eur J Paediatr Neurol 2014;18:420–426.
    OpenUrl
  21. 21.↵
    1. De Filippis R,
    2. Pancrazi L,
    3. Bjorgo K, et al
    . Expanding the phenotype associated with FOXG1 mutations and in vivo FoxG1 chromatin-binding dynamics. Clin Genet 2012;82:395–403.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Florian C,
    2. Bahi-Buisson N,
    3. Bienvenu T
    . FOXG1-Related disorders: from clinical description to molecular genetics. Mol Syndromol 2012;2:153–163.
    OpenUrlPubMed
  23. 23.↵
    1. Van der Aa N,
    2. Van den Bergh M,
    3. Ponomarenko N,
    4. Verstraete L,
    5. Ceulemans B,
    6. Storm K
    . Analysis of FOXG1 is highly recommended in male and female patients with Rett syndrome. Mol Syndromol 2011;1:290–293.
    OpenUrlPubMed
  24. 24.↵
    1. Seltzer LE,
    2. Paciorkowski AR
    . Genetic disorders associated with postnatal microcephaly. Am J Med Genet C Semin Med Genet 2014;166C:140–155.
    OpenUrl
  25. 25.↵
    1. Takanashi J,
    2. Barkovich AJ
    . The changing MR imaging appearance of polymicrogyria: a consequence of myelination. AJNR Am J Neuroradiol 2003;24:788–793.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Bahi-Buisson N,
    2. Poirier K,
    3. Boddaert N, et al
    . GPR56-related bilateral frontoparietal polymicrogyria: further evidence for an overlap with the cobblestone complex. Brain 2010;133:3194–3209.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. van der Knaap MS,
    2. Wolf NI
    . Hypomyelination versus delayed myelination. Ann Neurol 2010;68:115.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. El Chehadeh S,
    2. Faivre L,
    3. Mosca-Boidron AL, et al
    . Large national series of patients with Xq28 duplication involving MECP2: delineation of brain MRI abnormalities in 30 affected patients. Am J Med Genet A 2016;170A:116–129.
    OpenUrl
  29. 29.↵
    1. Syrbe S,
    2. Harms FL,
    3. Parrini E, et al
    . Delineating SPTAN1 associated phenotypes: from isolated epilepsy to encephalopathy with progressive brain atrophy. Brain 2017;140:2322–2336.
    OpenUrl
  30. 30.↵
    1. Edwards TJ,
    2. Sherr EH,
    3. Barkovich AJ,
    4. Richards LJ
    . Clinical, genetic and imaging findings identify new causes for corpus callosum development syndromes. Brain 2014;137:1579–1613.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Barkovich AJ,
    2. Kjos BO
    . Normal postnatal development of the corpus callosum as demonstrated by MR imaging. AJNR Am J Neuroradiol 1988;9:487–491.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Carecchio M,
    2. Mencacci NE
    . Emerging monogenic complex hyperkinetic disorders. Curr Neurol Neurosci Rep 2017;17:97.
    OpenUrl
  33. 33.↵
    1. Ma M,
    2. Adams HR,
    3. Seltzer LE,
    4. Dobyns WB,
    5. Paciorkowski AR
    . Phenotype differentiation of FOXG1 and MECP2 disorders: a new method for characterization of developmental encephalopathies. J Pediatr 2016;178:233–240 e210.
    OpenUrl

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Glossary
    • Methods
    • Results
    • Discussion
    • Affiliation
    • Author contributions
    • Study funding
    • Disclosure
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy

Dr. Jeffrey Allen and Dr. Nicholas Purcell

► Watch

Related Articles

  • No related articles found.

Topics Discussed

  • MRI
  • Rett Syndrome

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Views & Reviews
    STXBP1 encephalopathy
    A neurodevelopmental disorder including epilepsy
    Hannah Stamberger, Marina Nikanorova, Marjolein H. Willemsen et al.
    Neurology, February 10, 2016
  • Articles
    MeCP2 mutations in children with and without the phenotype of Rett syndrome
    K. Hoffbuhr, J. M. Devaney, B. LaFleur et al.
    Neurology, June 12, 2001
  • Article
    Not all SCN1A epileptic encephalopathies are Dravet syndrome
    Early profound Thr226Met phenotype
    Lynette G. Sadleir, Emily I. Mountier, Deepak Gill et al.
    Neurology, August 09, 2017
  • Articles
    Location and type of mutation in the LIS1 gene do not predict phenotypic severity
    G. Uyanik, D. J. Morris-Rosendahl, J. Stiegler et al.
    Neurology, July 30, 2007
Neurology Genetics: 9 (2)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Genetics | Online ISSN: 2376-7839

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise